Upstream / Downstream
Explore pathways related to this product.
Research More. Spend Less.
Spend $650 or more and get 20% off*
(*Offer valid in the US only. Expires June 30, 2017)
Find answers on our FAQs page.
- Additional protein information
- Analytical tools
CEACAM1 Antibody #5441
This product is discontinued
Gallery: CEACAM1 Antibody #5441
CEACAM1 Antibody detects endogenous levels of total CEACAM1 protein.
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala460 of human CEACAM1 protein. Antibodies are purified by protein A and peptide affinity chromatography.
CEACAM1 (also known as C-CAM and CD66a) is a member of CEA-related cell-adhesion molecule (CEACAM) subfamily of the carcinoembryonic antigen (CEA) family (1). CEACAM1 is expressed by certain epithelial, endothelial, lymphoid, and myeloid cells. Human CEACAM1 has many different splice variants; the abundance of CEACAM1 and the relative ratio of the different isoforms varies markedly among cell types and may be regulated in a context-dependent fashion. The isoforms with long (L) and short (S) cytoplasmic tails have different signaling properties. Notably, L isoforms contain a functional ITIM (immunoreceptor tyrosine-based inhibitory motif) and several serine and threonine residues that could serve as potential phosphorylation targets. The extracellular domain of CEACAM1 is heavily glycosylated, making its apparent molecular weight during electrophoresis much larger than its predicted size (57.6 kDa) (2). CEACAM1 mediates intercellular adhesion through homo- and heterophilic interaction with other members of the CEACAM family. Studies indicate that CEACAM1 plays important roles in angiogenesis, neovascularization, insulin signaling, T cell signaling, and tumorigenesis (3-8). In addition, CEACAM1 can function as a receptor for several microbial pathogens (9,10).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.